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Resumo 
 
 
  Os tumores cerebrais são a segunda neoplasia mais comum em crianças e a sua 
incidência é igualmente elevada na população adulta.  
Actualmente a classificação dos gliomas é baseada em características histológicas 
definidas pela Organização Mundial da Saúde (OMS) que os distingue em astrocitomas, 
oligodendrogliomas e ependimomas. Os oligodendrogliomas representam cerca de 10-
15% do total dos gliomas sendo o seu prognóstico mais favorável comparativamente aos 
restantes. Uma outra classificação, utilizada de forma complementar, baseia-se no grau de 
malignidade dos gliomas, permitindo a sua classificação entre o estadios I a IV de acordo 
com a sua malignidade, sendo os de nível IV os mais agressivos. Embora pareça que a 
classificação dos gliomas está bem estabelecida, a mesma padece de determinada 
subjectividade, sendo também limitadamente reprodutível uma vez que o desenvolvimento 
neoplásico pode ser impulsionado por diversas vias de sinalização que podem ser 
activadas ou silenciadas em paralelo, ou mesmo convergir para complexas interacções. 
Desta forma, a identificação de características biológicas para cada tipo de glioma é de 
extrema importância. Esta identificação pode ser realizada através do perfil de proteínas 
presentes nas células tumorais ou nos fluidos circundantes. Os perfis definidos podem não 
só fornecer indicações sobre a classificação do tumor, como também identificar 
biomarcadores clínicos e patológicos que levem ao desenvolvimento de tratamentos 
personalizados. 
Desta forma, com este trabalho pretendemos identificar novos potenciais 
marcadores para a classificação de oligodendrogliomas. Para alcançar o nosso objectivo, 
foram usadas amostras humanas de tecido não neoplásico e amostras de tecidos de 
pacientes com oligodendrogliomas de graus variáveis entre I e III. As avaliações destes 
marcadores foram realizadas por imunocitoquímica com o fim de quantificar a expressão 
de algumas moléculas associadas a processos como a proliferação e diferenciação (Sox-2 
e NG2, respectivamente), autofagia (LC3), endocitose (Caveolina-1), transdução de sinal 
(β-catenina) e multi-resistência a fármacos (P-glicoproteina), e ainda relativamente ao 
citosqueleto das células neuronais (neurofilamentos, NF) e a alterações na 
microvasculatura (CD31, α-actina). 
Pretendemos também com este trabalho comparar a expressão das moléculas 
referidas entre os diferentes graus de oligodendrogliomas e avaliar a possibilidade de 
classificar os diferentes estadios através da quantificação de novos marcadores.  
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Apesar dos resultados apresentados serem preliminares, acreditamos que poderão 
dar origem a conclusões bastante promissoras. Dos resultados obtidos, observou-se que 
os oligodendrogliomas, em comparação com amostras de controlo, apresentam níveis de 
expressão mais baixos de β-catenina e de α-actina e níveis mais elevados dos outros 
biomarcadores avaliados. Em particular, distinguimos como mais importantes pelo seu 
potencial como marcador específico para o diagnóstico de oligodendrogliomas de grau I, 
os marcadores Sox-2, NG2, P-gp, caveolina-1 e  α-actina e para oligodendrogliomas de 
grau III, a β-catenina, LC3, NF e o CD31.  
Assim podemos concluir que, através da realização deste trabalho, a maioria dos 
marcadores testados podem ser potencialmente usados para o diagnóstico, prognóstico e 
evolução dos oligodendrogliomas, fornecendo pistas que possam servir de auxílio ao 
tratamento deste tipo de tumor para o qual as opções terapêuticas são ainda bastante 
limitadas. 
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Abstract 
 
 
Brain tumors are the second most common neoplasm in children and its incidence is 
also relatively high in the adult population, with gliomas accounting for the majority of 
cases. The World Health Organization (WHO) classification distinguishes astrocytomas, 
oligodendrogliomas and ependymomas, based on the histological characteristics of tumor 
cells. Oligodendrogliomas accomplish about 10-15% of total gliomas and are the ones with 
a better prognostic. A complementary classification based on glioma malignancy, allows 
the grading of these tumors from grade I to IV (the most aggressive ones). Although it 
seems that the classification of gliomas is well established, these classifications have 
subjective criteria and lack reproducibility since the neoplastic process is driven by too 
many signalling pathways that can be activated or silenced in parallel, or even converge to 
complex interactions. Thus, identifying biological signatures of each glioma subtype 
through protein biomarker profiling of tumor or tumor-proximal fluids is therefore of high 
priority. Such profiling not only may provide clues regarding tumor classification but may 
identify as well clinical biomarkers and pathologic targets for the development of 
personalized treatments. 
Therefore, with this work we aim to identify potential new biomarkers for the 
classification of oligodendrogliomas. To accomplish our goal, human samples from normal 
tissue and from patients with oligodendrogliomas (grades I to III) will be studied by 
immunocytochemistry in order to quantify the expression of some molecules associated 
with proliferation and differentiation processes (Sox-2 and NG2), autophagy (LC3), 
endocytosis (caveolin-1), signal transduction (β-catenin), neuronal cells cytoskeleton 
(neurofilaments, NF), microvasculature changes (CD31, α-actin) and multidrug resistance 
protein  (P-glycoprotein).  We will evaluate how the expression of these proteins varies 
between the different oligodendroglioma grades and we will look on whether it is possible 
to classify them accordingly to the presence of these new biomarkers for gliomas. 
Although preliminary, we believe that our results give rise to very promising 
conclusions. We have observed that, as compared to control samples, oligodendrogliomas 
show a lower expression of β-catenin and α-actin, but a higher expression of other 
biomarkers. In particular, Sox-2, NG2, P-gp, caveolin-1 and α-actin revealed to be potential 
biomarkers to be used for the diagnosis of oligodendrogliomas type I, while β-catenin, LC3, 
NF and CD31 revealed to be potential biomarkers for the diagnosis of oligodendrogliomas 
type III. Thus, we may conclude that most of the tested biomarkers can be potentially used 
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for oligodendroglioma diagnosis, prognosis and surveillance, providing clues to assist 
therapeutic decisions of this still untreatable brain cancer. 
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I. Introduction 
1. Organization of the Brain 
 
1.1. Brain anatomy 
 
The central nervous system (CNS) is the most amazing structure in human being 
considered as the major controlling, regulatory and communicating system, able to receive 
and interpret millions of informations from the inside or outside of the body. An introductory 
description of the brain anatomy is a basic, although essential topic of this thesis, due to 
the frequent references to various structures of the brain. Thus, this brief summary on the 
major regions of the CNS intends to help the reader to further understand all the used 
terminology. 
CNS is composed by two main parts: brain and spinal cord which are continuous at the 
foramen magnum. Due to their vital importance, these structures are protected from injury 
by a bony skull. The brain is located in the cranial vault and the spinal cord is placed in the 
vertebral column (1-3). 
Considering brain, this organ can be divided into three main structures: forebrain, 
midbrain and hindbrain. The forebrain is the largest portion of the brain since it contains the 
cerebrum, the corpus callosum and the diencephalon. The midbrain (or mesencephalon) 
connects the pons and the cerebellum with the cerebral hemispheres. The hindbrain is the 
region consisting of the medulla oblongata, pons and cerebellum (1). All the structures of 
the brain are surrounded by connective tissue membranes, called meninges, and fluid-filled 
spaces named ventricles (2, 3). 
The cerebrum is divided into two hemispheres by a deep longitudinal fissure 
(interhemispheric fissure) and connected by the corpus callosum. The outer surfaces of the 
hemispheres (cerebral cortex) are composed by many gyri or convolutions caused by 
infolding of the cortex, separated by sulcus or fissures (Fig.I.1) (1-3). The hemispheres are 
identically divided into four lobes, which names derived from the cranial bones that overlie 
them and the location that they assume in the brain. The four lobes, occipital, temporal, 
parietal and frontal were originally a mere anatomical classification (1, 2). Currently they 
have been related with the capacity to process and initiate distinct functions such as motor 
activities, vision and perception of auditory and olfactory stimuli, memory and speech (2, 3). 
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The diencephalon is composed by the thalamus and hypothalamus and is located 
between corpus callosum and brainstem. Thalamus is important to process sensorial 
information and the hypothalamus controls emotions, autonomic and endocrine functions 
(1-3). 
 
                                                                                             
        
                                                     
                                                                                                   
            
                                                                              
            
   
                                                                                                         
        
Fig. I.1 – Drawing of the human brain from a top view. The paired cerebral hemispheres are 
divided by a deep longitudinal fissure (interhemispheric fissure). The outer surfaces of these 
hemispheres display many gyri or convolutions separated by sulcus or fissures. 
 
Within the brain, there are areas dominated by grayish appearance while others appear 
as white mater (Fig. I.2). 
The gray matter is located on the surface of the hemispheres and is composed of 
neuronal cell bodies, glial cells and blood vessels. The white matter is located in deeper 
nuclei and it mainly consists of nerve fibers that cover the axons (2). 
 
 
 
Fig. I.2 – Simplified view of the gray and white mater location in a transversal section of the 
human brain. The gray matter is situated on the surface of the hemispheres and made up by cell 
bodies, while the white matter is located in deeper nuclei and composed by nerve fibers. 
 
Sulcus 
Gyri 
Cerebellum 
Interhemispheric fissure
Left cerebral hemisphere 
Right cerebral hemisphere 
Anterior Posterior 
White matter 
Gray matter 
Ventricles 
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The cerebellum is in the posterior part of the brain and it is connected to the pons 
and medulla oblongata. Cerebellum is essential for the coordination of movements and 
learning of motor tasks.  Pons is related to somatic and visceral motor control while 
medulla oblongata controls autonomic functions (Fig. I.3) (1-3). 
 
 
 
a)            
  
      
 
 
      
        
        
 
b) 
 
 
 
 
 
 
 
 
 
Fig. I.3 – Human brain diagram: lateral view (a) and midsagittal view (b). In the lateral view it 
can be visualized the four lobes of the brain, with cerebellum and corpus callosum visualized in the 
midsagittal view. 
 
Medulla oblongata is continuous with the spinal cord which extends from the foramen 
magnum at the base of the skull to the level of the first lumbar vertebra. The spinal cord 
receives and processes sensory information and controls movement of the limbs and the 
trunk (1, 2).  
 
 
 
 
Parietal lobe 
Occipital lobe 
Cerebellum 
Medulla oblongata 
Frontal lobe 
Corpus callosum 
Diencephalon 
Pons 
Parietal lobe 
Occipital lobe 
Cerebellum 
Medulla oblongata 
Frontal lobe 
Pons 
Temporal lobe 
Anterior Posterior 
 1.2. Cellular components of the brain
 
The CNS being such a complex and essential structure requires a highly specialized 
system to maintain a stable environment. With this purpose, CNS is separated from 
circulatory system by a dynamic interface called blood
by Lewandowski in 1900. This barrier limits the entry of several components such as red 
blood cells, leukocytes and plasma components into the brain 
barrier to many components 
structure and function of the BBB depends on the interaction between several different cell 
types (Fig. I.4).  
Despite the complexity of the nervous system and the tremendous number of cells, 
there are only two main types of cells in 
(microglia, astrocytes, and oligodendrocytes)
the brain, assisting in nervous system repair and maintenance, in synapse elimination, and 
providing metabolic functions to
system and the responsible to transmit impulses. Glial cells are 
structural filler, since they highly 
contributing to maintain the inte
Fig. I.4 - Schematic view of the 
The “neurovascular unit” that is essential for the health and function of CNS
cerebral microvascular endothelium, 
oligodendrocytes and astrocytes), together with the extracellular matrix
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-brain barrier (BBB), first introduce
(4). It serves also as a 
located inside the brain, preventing them from leaving it
the nervous tissue: neurons and glial cells
 with several functions that include 
 neurons. Neurons are the structural unit of the nervous 
much m
contribute to keep the functional homeostasis of the brain
grity of the neurons (5). 
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 1.2.1. Neuronal cells
 
The neuron is an electrically excitable cell
and transmit information. These cells are highly specialized and
the structure of a typical neuron.
Fig. I.5 -  Drawing of a neuron
axon. 
 
The neuron is composed by three basic parts: cell body or soma, one or more 
dendrites and a unique axon.
to other types of cells. It has a nucleus with at least one nucleolus and contains many of 
the typical cytoplasmic organelles that provide energy and synthesize organic materials, 
especially neurotransmitters
The lack of centrioles is consistent to their amitotic nature, since the function of centrioles is 
related with cell division. Additionally, the cytoplasm contains clusters of roug
endoplasmic reticulum and free ribosomes, called Nissl bodies, which account for the dark 
color of the gray matter (3, 6
The dendrites and axons are cytoplasmic extensions that 
Dendrites are usually short and branched (rarely longer than 1
receiving and processing, from other neurons, the majority of the excitatory synaptic inputs. 
Due to their actin cytoskeleton, microtubules and
dendrites are stable extensions 
neurons have hundreds of small protrusions 
(3). Some authors refer that abnormalities in the number, size and morphology of dendrites 
and their respective dendritic spines, can be associated with several diseases
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 amitotic.
 
 
.  A typical neuron is constituted by cell body, dendrites and a 
 The cell body is the central part of the neuron and is similar 
 that are important molecules in cell-to-cell communication. 
). 
project from the cell body. 
-2 mm) specialized for 
 microtubule-associated proteins, 
that serve to increase the surface area of the cell
along the dendrites known as dendritic spines 
Cell body
Dendrites
Axon 
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The axon is usually elongated and it carries impulses away from the cell body up to a 
meter or more away. An axon may have infrequent branches called axon collaterals. Axons 
and axon collaterals terminate in many short branches or telodendria. The distal ends of 
the telodendria are slightly enlarged to form synaptic bulbs. Many axons are surrounded by 
a segmented, white and fatty called myelin or myelin sheath. Myelinated fibers make up the 
white matter of the CNS. The unmyelinated regions between the myelin segments are 
called the nodes of Ranvier (2). 
 
1.2.2. Glial cells 
 
The name glial (meaning "glue") reflects the original concept that glial cells were 
merely supportive cells for neurons. Currently it has become apparent that glial cells are 
not only supportive cells but instead they play a number of important active functions (7). 
They comprise 90% of the brain's cells and are capable of mitosis, but they do not conduct 
nerve impulses. These cells perform a plethora of important functions, as they can provide 
support for the brain, assist in nervous system repair and maintenance, produce myelin for 
neurons and also supply physic, nutritional and oxygen support for neuronal cells (7, 8). 
Four types of glial cells are usually considered on CNS: macroglial cells (which 
consist of astrocytes and oligodendrocytes), microglia cells, NG2 cells and ependymal cells 
(7, 8). 
 
1.2.2.1. Astrocytes 
 
Astrocytes, also known by astroglia, are star-shaped cells (Fig. I.6) that make up the 
largest glial population cells (9). 
They exert structural functions, are required for neuronal survival, neurite formation 
and angiogenesis, and maintain CNS homeostasis by regulating pH, ionic concentrations 
and osmolarity (10). Astrocytes also provide metabolic support to neurons by fueling their 
activity with energy and substrates, while removing excess neurotransmitter molecules 
from the extracellular space (11). These cells also form the neurovascular unit of the BBB 
since their end-feet wrap around the capillary surface (12). These cells can induce tight 
junctions in endothelial cells, thus participating in the regulation of BBB permeability (13). 
 Fig. I.6 - Drawing of astrocyt
be classified as protoplasmic (a) or fibrous (b).
 
Astrocytes are usually
astrocytes. The location and morphology of these two types of astrocytes are different. 
While protoplasmic astrocytes are distributed in grey matter and have a large, flat and 
round cell body, wide processes and few branches
in white matter and are typically
Astrocytes can be identified histologically by their expression 
protein (GFAP), a specific intermediate filament 
cells. This is a useful tool to evaluate the presence of these cells in brain samples
 
1.2.2.2. Microglial cells
 
Microglial cells are believed to originate from myeloid cells and comprise 
approximately 5 to 12% of the brain 
macrophages in CNS as they are described to be part of the innate immune response in 
the brain. Thus, microglial cells can phagoc
(18, 20-23). 
Microglial cells develop in the brain and spinal cord and are distributed througho
the gray and white matter. It is known that these cells develop a branched form with 
intimate interaction with neurons and other glial cells. Historically, descriptions of microglia 
report remarkable morphological transformations in response to tissue i
including CNS infections, neuroin
diseases (8, 20).  
Although the exact role of microglia cells in CNS development, homeostasis, and 
disease remain almost unknown, resting microglial cells are described to exhibit a 
a) 
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characteristic ramified morphology and are responsible for immune surveillance. However, 
in response to brain injury or to immunological stimuli they become rapidly activated and 
undergo dramatic morphologic alterations to an amoeboid state (8, 18, 20, 23). An 
unregulated response or overactivation of microglia cells can have devastating neurotoxic 
consequences. Thus, depending on the progression of the disease and the type of 
stimulus, microglia activated cells can have neurotoxic or neuroprotective properties (20). 
Concerning the phenotype markers of these cells, calcium-binding protein (Iba-1) 
stands out from others markers, being often used as a marker of microglia.  Nevertheless, 
since Iba-1 it is also expressed by most tissue macrophages, it cannot be used to 
differentiate between tissue resident microglia and other tissue macrophages (8).  
 
1.2.2.3. Oligodendrocytes 
 
Oligodendrocytes are the myelinating cells of the CNS and constitute about 5 to 
10% of the total glial population. Oligodendrocytes have compact and uniform dark nuclei, 
a small round body and about four to six branching processes (24). 
These cells wrap themselves around part of the surrounding axons forming myelin, 
an insulating lipid-rich membrane sheath that speeds the conduction of electrical impulses 
(Fig. I.7) and they are able to myelinate more than sixty axons (24, 25). The major 
components of myelin are lipids, which represent about 70% of the total composition. The 
remaining 30% are proteins, such as the myelin basic protein (MBP), proteolipid protein 
(PLP) and 2′,3′-cyclic nucleotide 3′-phosphodiesterase (CNP). These three proteins 
together comprise the main protein components of myelin (24). The principal physiologic 
function of myelin is to conduct, in a high velocity, the potential action in the axon. 
Moreover, periodic gaps (node of ranvier) in the insulating sheath on the axon of certain 
neurons serve to facilitate the rapid conduction of nerve impulses. The conduction 
performed  by saltatory mode is much faster comparing to the unmyelinated axon of the 
same diameter (24). 
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Fig. I.7 -  Oligodendrocytes are myelinating cells that surround the neurons. These cells 
provide support to neurons and produce large amounts of specialized membrane (myelin) that form 
multiple wraps around the contracted axons. 
 
Two of the most important functions of oligodendrocytes are the promotion in axonal 
conduction and the regulation of neuronal properties by maintaining axonal integrity (24, 
25).  A large number of brain´s diseases have been reported to be related with 
modifications in oligodendrocytes. These modifications are associated with the decrease in 
oligodendrocyte number and density, as well as with an abnormal myelin morphology. In 
some disorders, imaging studies using tensor imaging revealed a decrease in white matter 
integrity that may subsist prior to disease onset (24, 25). Thus, many studies have been 
made in order to promote myelin repair, delaying the disease progression, and to recover 
the loss of neurological functions. 
The origin of oligodendrocytes is still disputed, however, recent studies indicate that 
in spinal cord most oligodendrocytes derive from a specific domain in ventricular zone, 
which give rise to oligodendrocyte precursor cells (OPC) that migrate to their final location 
and then differentiate (24, 26, 27). During the progression along oligodendroglial lineage, 
several markers are expressed in specific stages of cell maturation. In this context, these 
makers, as well as the morphologic complexity and the migratory capacity, can contribute 
to distinguish the different stages of oligodendrocyte maturation. Initially, OPC express 
some specific markers like chondroitin sulfate proteoglycan NG2, ganglioside A2B5 
and platelet-derived growth factor receptor alpha (PDGFRA). During the differentiation 
process these cells give rise to pre-oligodendrocytes that express, in addition to OPC 
markers, the sulfatide recognized by the O4 antibody. After loss of A2B5 and NG2 markers, 
the immature oligodendrocytes continue to express O4 and start the expression of 
galactocerebroside C (GalC). Finally, mature oligodendrocytes are able to produce the 
myelin proteins, such as MBP, proteolipid protein PLP, myelin associated glycoprotein 
Oligodendrocyte
Axons 
Branching processes 
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(MAG) and myelin oligodendrocyte glycoprotein (MOG) (24, 26-28). In addition, many 
transcription factors have been implicated in the specification of different stages of 
oligodendrocyte maturation. Regarding that, one of the best known transcription factors are 
the Olig genes, Olig1 and Olig2. Expression of Olig2 occurs during all stages of 
oligodendrocyte maturation and is required for the development of NG2 positive progenitor 
cells (29, 30). On the other hand, Olig1 appears to be mostly implicated in 
oligodendrocytes maturation, being involved in the final stages of myelin production (30, 
31). 
 
1.2.2.4. Ependymal cells 
 
Ependymal cells are ciliated cells coating the ventricular walls of the brain and the 
central canal in the spinal cord. These cells are important for the propulsion of 
cerebrospinal fluid (CSF), provide a barrier to the parenchyma and have recently been 
related to neuroendocrine functions (32).  
Other type of cells, choroid ependymocytes, occupy an important position 
interposed between fenestrated blood capillaries of the choroid plexus and the CSF, where 
they constitute an active blood-CSF barrier, also playing a role in the production of this 
ventricular fluid (2, 3). 
 
1.2.3. Other non-neuronal cells 
 
Related to cells in the CNS, it has been describe that other type of cells, pericytes, 
in spite of not being neural cells, are imperative for the CNS integrity and maintenance. For 
this reason we will add to the introduction section, a brief topic concerning these cells. 
 
1.2.3.1. Pericytes 
 
Pericytes play an integral role in the maintenance of the BBB as well as in several 
other homeostatic and hemostatic functions of the brain (33). These cells are also a key 
component of the neurovascular unit, which further includes endothelial cells, the basement 
membrane, astrocytes, microglia and neurons (22) as previously indicated.  
Pericytes exhibit multipolar primary processes extending along the longitudinal axis 
of capillaries and secondary branches wrapping around the vessels enveloped in the 
basement membrane and in direct contact with endothelial cells (Fig. I.8) (34). Thus, these 
 cells are responsible for a variety of functions such as capillary blood flow regulation, 
modulation of BBB permeability 
can also stabilize and monitor the maturation of endothelial cells by direct co
across the basement membrane, as well 
shown, in recent studies, that the lack of pericytes in the CNS can cause the breakdo
the BBB and lead to other degenerative changes in the brain
 
 
Fig. I.8 - Pericytes are contractile cells that 
have a close physical association with 
endothelial cells. 
 
Pericytes are known to express multiple
muscle actin, NG2, PDGFR
and II, and also desmin (34
marker expression suggesting the existence of pericyte heterogeneity. For instance, there 
are some pericyte subpopulations that lack 
Indeed, only those located near arterioles in the brain are positive
negatively stained in fresh 
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and clearance and phagocytosis of cellular debris
as by paracrine signaling (35
 (33). 
 
wrap around the endothelial
the endothelium, sharing the basement membrane with the 
 immunologic markers such as 
-α, PDGFR-β, major histocompatibility complex (MHC) class I 
). However, not all pericyte subpopulations display the same 
α-smooth muscle actin expression 
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primary cultures (36). 
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2. Brain tumors: Gliomas 
 
In general, a brain tumor is characterized by an abnormal mass of cells growing in the 
brain. It develops from abnormal cells that have the ability to multiply uncontrollably for 
multiple or unknown reasons. This mass of cells can be divided into two main groups: 
benign and malignant. In clinical practice, a benign tumor is not considered cancerous. 
Their capacity to grow is slow and they can be usually removed. Recidives in benign tumor 
are not recurrent and cells do not spread or invade other tissues. In contrast, malignant 
tumors are cancerous, grow fast and can invade and damage nearby tissues or organs 
also having the capacity to metastasize (37). However, this classification is not trivial since 
a tumor with benign characteristics may be considered malignant if it is located in a critical 
area or its size is life-threatening. 
The ability of cancer cells to disconnect from the malignant mass, enter the 
bloodstream or lymphatic system to form tumors in other parts of the body is called 
metastasis. For this reason, a tumor can be primary or secondary. A primary brain tumor 
arise “de novo” in brain. Secondary brain tumor is originated from cells which arise from 
other tissue or organ and spread into healthy areas (37).  
Brain tumors have an incidence of 12.8 per 100,000 people (38, 39) and a median 
survival of 14 months (40).They are usually caused by a change in genetic structure, such 
as mutated or missing genes resulting in abnormal cells. Gliomas are the most common 
primary brain tumor accounting for more than 70% of total primary malignant intracranial 
tumor (41, 42). Some controversy still exists in turn of the real origin of gliomas (41). 
Nevertheless, some studies have demonstrated that these tumors can consist of a 
heterogenous mixture of several glial phenotypes that goes from immature cell types, 
through poorly differentiated cells to mature cells (43). This heterogeneity leads to vary 
different courses of gliomas compromising prognosis and therapy. 
Due to the diversity of gliomas, it was required to establish a unique classification in 
order to be followed by the clinical community worldwilde. In this context the WHO 
proposed a universal classification of CNS tumors. The present thesis is focus in WHO 
classification of gliomas. So, the following section intends to provide some concepts to be 
taking into account when considering the sample profiling used in the present work. 
 
 
 
 
 
 2.1. WHO classification
 
In 1993, the WHO created their first guideline for comprehensive classification of 
neoplasms affecting the CNS. Recently, in 2007, the WHO published a review of their 
classification of tumors where several neoplasms were included. This classification is 
based mainly on three parameters
 
2.1.1. Classification based on cell types
 
Despite the knowledge regarding the origin of gliomas 
the cell type from which gliomas are
heterogeneity. This classification is based on histological similarities involving gliomas and 
normal glial cells such as astrocytes, oligodendrocytes and ependymal cells. Thereb
gliomas can be classified as astrocytomas, oligodendrogliomas and ependymomas, 
respectively (Fig. I.9). Tumors displaying a mixture of different cells are designated by 
oligoastrocytomas (or mixed gliomas) 
oligodendrogliomas are the goal of this work.
 
                                 
Fig. I.9 - Glial cell types and associated tumors of CNS. 
categories based on their cell origin, in accordance to World Health Organization
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Oligoastrocytoma
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2.1.2. Classification based on malignancy grade 
 
The WHO grading scheme for glial neoplasms assigns four distinct stages (from 
Grade I to Grade IV). Accurate scaling of glioma facilitates the treatment and the prediction 
of their outcome. The grade designates its degree of malignancy and it is acquired based 
on the tumor’s histopathology using the following features: similarity to normal cells 
(atypia), rate of growth (mitotic index), indication of uncontrolled growth, dead cancer cells 
in the center of the tumor (necrosis), potential for invasion (infiltration) and blood supply 
(vascularisation) (42).  
Grade I gliomas are the less malignant tumors, sometimes considered benign and 
are typically related with long-term survival (46, 47). The median survival for these patients 
is between 5 and 10 years compared with a survival of about 14 months in patients with 
malignant glioma (48, 49). These tumors exhibit a slow grow, a limited cell proliferation 
potential and have an almost normal appearance by microscope observation (47, 50). 
These tumors are not likely to spread. Grade II tumors have a relatively slow growing rate, 
a low-level of proliferative activity and a slightly abnormal microscopic appearance. Some 
of these tumors are infiltrative and can either recur or progress to a higher-grade glioma 
(44, 50). Grade III tumors are, by definition, malignant. The cells of a grade III tumor are 
actively reproducing abnormal cells, which grow into nearby normal brain tissue. These 
tumors tend to recur, often as the higher grade IV, which are the most malignant. When 
gliomas contain several grades, the malignancy is established by the highest malignant 
grade of the cells, even if most of the tumor is of a lower grade kind.  
Regarding oligodendrogliomas, the main focus of the present work, they can be 
classified in low-grade/WHO Grades I and II (Oligodendroglioma I and II, respectively) or 
high-grade/WHO Grade III (Anaplastic Oligodendrogliomas). Concerning low-grade 
oligodendrogliomas, grade I is almost inexistent and there are few studies regarding these 
tumors. Oligodendrogliomas are also found in oligoastrocytomas, generally related to the 
grade IV, but not exclusive of this degree (51, 52). Typically, oligodendrogliomas progress 
from low grade lesions into high grade but this natural progression may not be seen in 
some patients (53). Fig.I.10 shows the classical progression of oligodendrogliomas. 
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Fig. I.10 - Oligodendroglioma grades. Oligodendrogliomas can be divided into three categories 
based on their malignant grade and general tumour characteristics, in accordance to World Health 
Organization. 
 
2.1.3. Classification based on tumor location 
 
Gliomas can also be classified according to their location, whether above or below the 
tentorium, a membrane that separates the cerebrum (above) from the cerebellum (bellow). 
Hence, they are defined as supratentorial, which develop above the tentorium, and as 
infratentorial, which develop below the tentorium (44).  
 
2.2. Oligodendrogliomas: Definition and Grade 
 
As described above, oligodrendrogliomas are usually divided into low-grade tumors 
(grade I and II) and high-grade tumors (grade III) (51) since, in general, grade IV also 
consider the presence of astrocytomas.  
Currently, clinical evaluation is made by routine hematoxylin- eosin. When observed in 
a microscope, grades I and II show tumour cells arranged in a solid or honeycomb 
appearance. The cells are usually small and rounded with a well-defined nucleus 
surrounded by a perinuclear clear halo. Grade II can also exhibit calcifications (52, 54). 
Histological examination of anaplastic oligodendrogliomas shows an aggressive form of 
oligodendrogliomas often associated with increased cellularity, nuclear atypia and 
widespread mitotic activity and apoptosis. Haemorrhage, tumor necrosis, calcification and 
microvascular proliferation may be present, but are variable in severity and extent (52, 55). 
Oligoastrocytomas show a bizarre appearance, have a high mitotic activity and can 
easily spread into the surrounding normal brain tissue. These tumors have also an 
enormous ability to form new blood vessels (angiogenesis) so they can maintain their rapid 
growth. Necrotic zones are usually associated with a rapid evolution and fatal outcome (44, 
56). The vast majority of oligoastrocytomas do not contain distinct and separate areas with 
Malignancy 
Oligodendrocyte Oligodendroglioma 
I 
Oligodendroglioma 
II 
Anaplastic 
Oligodendroglioma 
 well-defined oligodendroglial and astrocytic morphology;
oligoastrocytomas this may occur. Fig.I
classification of oligodendrogliomas and oligoastrocytomas.
  
Fig. I.11 - Histopathological
Oligodendrocytes in normal brain white matter (A), 
and delicate chromatin pattern and a perinuclear halo. Low
some calcifications (white arrows). Anaplastic oligodendroglioma (C) is characterized by a higher 
number of cells and blood vessel
and oligodendrogliomas (left). 
D which show magnification x100 
 
Oligodendrogliomas comprise about 4% of primary intracranial tumor, representing 
about 10-15% of the gliomas 
between 30-50 years with a higher incidence in male than 
tumors an age and gender
relatively rare form of cancer, their location in the brain is commonly problematic 
accounting to high morbidity and mortality 
and 63.6% for 10 years, which also depend
6% of these tumors are found in infants and children which are 
survival rates (93% for 5 years) 
Oligodendrogliomas have more susceptibility to invade cerebral hemispheres in the 
white matter of the frontal lobe but they can also occur in other locations such as 
A
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cerebellum, brainstem and spinal cord (60, 61). Even though oligodendrogliomas rarely 
metastasize outside the brain, they are capable to spread extensively into surrounding 
normal brain tissue (42). 
Diverse studies had shown that oligodendrogliomas have better prognosis and are 
more sensitive to chemotherapy than other gliomas with the same WHO grade. In this way, 
it is very important an accurate diagnosis in order to predict the survival rate (52, 62).  
 
2.3. Symptoms and diagnosis 
 
Brain tumors may have a variety of warning signs ranging from pain to stroke. Different 
parts of the brain control different functions, so symptoms will vary depending on the 
tumor's location, type and size of tumor. However, possible symptoms of a brain tumor can 
be headaches, seizures, hearing and vision loss, sensory and motor loss, changes in 
behavior, weakness and difficulty with short-term memory (63). Usually, gliomas (in most 
cases oligodendrogliomas) that affect the temporal lobe are silent causing few symptoms 
and sometimes, seizures and language problems (39). 
For a complete diagnosis, it is useful to perform an entire physical and neurological 
examination. Depending on the results of the physical and neurological examinations, other 
strategies can be applied such as computerized tomography or computerized axial 
tomography, magnetic resonance imaging, angiogram or arteriogram and brain scan. 
Recently, these tests are being replaced by positron emission tomography scanning due to 
its superior resolution and accuracy. Surgical biopsies of brain can also be used (62, 64).  
An accurate distinction between the different glioma types is crucial for prognostic and 
therapeutic implications. As seen before, histopathology represents the gold standard for 
typing and grading gliomas and relies largely on particular architectural similarities of tumor 
cells with non neoplastic glial cells (47, 65, 66). However, this type of classification is not 
trivial and is strongly associated with interobserver variability (47, 67) presenting 
discrepancies ranging from 23 to 43% (66). This clearly impacts on treatment decision and 
on the outcome and interpretation of clinical studies. Thus,  the availability of molecular 
biomarkers or signature protein patterns identified from plasma or tumor biopsies, may 
have potential to improve routine diagnosis (66). 
Some authors claim that the knowledge of the genetic alterations that can occur in the 
various types and malignancy grades of glioma can be useful to classify tumors in clinical 
practice. In this regard, various studies have been done to understand genetic mutations. 
Recently, three molecular markers stand out from others assuming an important 
role in the diagnosis and/or prognosis of gliomas: 1p/19q co-deletion, isocitrate 
dehydrogenase (IDH) mutations and O-methylguanylmethyltransferase (MGMT) promoter 
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methylation (60, 63, 68). The detection of these mutations is usually predictive of a 
favorable prognosis as it is associated with longer progression-free time and longer median 
survival time (47, 57, 62). These mutations can be detected by different techniques 
including polymerase chain reaction, fluorescent in situ hybridization and array-based 
comparative genomic hybridization (52). Other mutations also found in oligodendrogliomas 
are loss of chromosome 9p, loss of the tumor suppressor genes CDKN2A and CDKN2B, 
mutation/deletion of RB1 and loss of chromosome 10q. Experts in the investigation of 
gliomas claimed that some genetic mutations are linked to tumor locations. Table I.1 
illustrates the most important genetic mutations in oligodendrogliomas.  
 
Table I.1- Molecular markers used on diagnosis, prognosis and predictive behavior of 
oligodendrogliomas in patients. 
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Chromosomal 
Type of mutation Tumor Location Clinical Application 
1p/19q (47) Co-deletion  
Frontal, parietal 
and 
occipital lobes 
Diagnosis and 
Prognosis  
9q and/or 10q 
(46) 
Loss Inconsistent data 
Prognosis 
Genomic 
 
MGMT (47) Hypermethylation  
 
Prognosis and 
Predictive 
IDH (47) Somatic 
mutations 
Frontal lobe 
Diagnosis and 
Prognosis  
CDKN2A/B (69) Hypermethylation 
and Deletion  
Inconsistent data Predictive 
RB1 (70) Hypermethylation Inconsistent data Predictive 
 
MGMT - O–methylguanylmethyltransferase; IDH - Isocitrate dehydrogenase; CDKN2A - cyclin-dependent 
kinase inhibitor 2A; CDKN2B - cyclin-dependent kinase inhibitor 2B; RB1 - retinoblastoma-associated protein. 
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2.4. Treatment 
 
Despite advances in glioma therapy, current strategies are still suboptimal. The 
therapeutic decisions may involve single or combined therapies of surgery, radiotherapy 
and chemotherapy, depending on the location and the degree of malignancy. In a clinical 
point of view, a tumor grade is a key factor influencing the choice of therapies, particularly 
determining the use of adjuvant radiation and specific chemotherapy protocols (71, 72). 
Table I.2 shows the treatment usually applied in different types of oligodendrogliomas. 
 
Table I.2- Scheme therapy for the different types of oligodendrogliomas. 
Tumor Treatment Optional treatment 
Oligodendroglioma I and II S R 
Oligodendroglioma III S+R C 
Oligoastrocytoma S+R C 
 
S-surgery; R-radiation therapy; C-chemotherapy. Based on Higuchi (2004) and Cairncross (2004) 
(73, 74) 
 
Surgery is the first line of treatment strategy, once the exact location of the tumor is 
confirmed, except in infants and young children in which chemotherapy is the only therapy. 
The tumor tissue that is removed during surgery can be used for histopathological 
evaluation and diagnosis, and to decide further treatment. The aim of the surgery is to 
remove all of the tumor and when possible a safety margin of 2-3 cm (62). However, in 
most cases, tumor tends to spread into surrounding vital tissues and its removal can cause 
new neurologic deficits (62). With the purpose to complement surgery, radiation therapy 
normally follows surgery (71). 
When using radiation, therapy is directed to the tumor site and, when possible, 
expanded to a safety margin of 2-3 cm in order to reach a most complete removal of the 
tumor. Unfortunately, sometimes complete removal is not possible, but rather a decrease 
on the tumor volume (71). Radiation is administered in restricted margins and every 
attempt should be taking into account to avoid radiation outside the tumor (75).  
The use of chemotherapy associated with radiotherapy as been controversial since 
a variety of studies revealed no significant benefit comparing with the merely use of 
radiotherapy. Nevertheless, this combination of treatments is occasionally used in order to 
relieve the symptoms of the brain tumor.  
Due to the cytotoxic effects of chemotherapy in healthy tissues, this strategy is not 
considered the standard treatment of gliomas. However, for the first time in CNS 
neoplasms history, several studies revealed an association between genetic changes, 
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chemotherapy and predictive outcome percentage demonstrating that more than 50% of 
oligodendroglioma have a high-response to chemotherapy. Thus, researchers have 
attempted an association between 1p/19q co-deletion and a favorable response to 
chemotherapy as well as to radiotherapy (57). 
However, MGMT promoter methylation and IDH mutations displayed longer 
progression-free and higher survival rates independently of genotoxic treatment (62).   
Cytotoxic therapy includes procarbazine, vincristine and lomustine (or CCNU). 
Usually these three drugs are used in combined therapy having a specific regimen known 
as the PVC. Temozolomide has recently been reported as an alternative to PVC regimens 
demonstrating the same effectiveness but better toleration (62).  
Other chemotherapy drugs such as bevacizumab, paclitaxel, irinotecan, carboplatin 
and etoposide have shown some  additival effects as a second line chemotherapy, 
especially in higher grade tumors (63). Recently, new therapies have emerged in glioma 
treatment such as biological therapy or immunotherapy. However, the effectiveness of 
these strategies is still under investigation.  Another new therapy is the gene therapy, a 
promising method under investigation which seems to be helpful in controlling tumor growth 
(71, 76). 
Gliomas are difficult to treat due to several reasons. The first main obstacle is the fact 
that some drugs cannot get into gliomas directly because of the BBB. On the other hand, 
since gliomas can have more than one type of tumor cells and chemotherapy is mostly 
directed at one kind of tumor cells, this treatment will not target all neoplasic cells (17).  
Another important point to consider is the existence of proteins at the cell membrane 
surface that interfere in the cell treatment by promoting the efflux of the pharmaceuticals 
(see section 3.3.7).  
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3. Glioma biomarkers 
 
The genetic mutations on cancer cells result in a heterogeneous disease characterized 
by modifications on expression and activity of important cellular proteins, particularly if 
occurring in a subset of oncogenes and tumor suppressor genes. This genomic instability 
leads to consequent variations in cancer cells concerning metabolism, proliferation and 
metastasis (77, 78). Thus, the recognition of molecular biomarkers has been an important 
issue to consider in diagnosis, prognosis and treatment of human cancers. For instance, in 
breast cancer, the presence of the human epidermal growth factor receptor 2 (HER2) is 
associated with clinical resistance to cytotoxic and hormone therapy, indicating the use of a 
specific drug, trastuzumab, that directly induces apoptosis (17, 79). Also, the  prostate-
specific antigen, is widely used to screen and to make the diagnosis of prostate cancer 
(17). 
There are still some challenges in identifying and verifying potential glioma biomarkers 
as not all proteins can be useful for this function. Instead they may obey to several 
characteristics, which will be discussed in the next section. 
 
3.1. Characteristics of a biomarker 
 
A biomarker is a molecular unit available to be measured objectively, demonstrating 
specific and reproductive characteristics in normal biological processes, pathogenic events 
or in a pharmacological response to a therapeutic interference. Biomarkers can be 
released either by cancerous cells or by other tissues or cells which respond to the 
presence of tumor cells (38).  
There is no rule whether a cellular component become a biomarker; however, it must 
comply particular characteristics in which the most important is the capacity to provide 
distinctive diagnostic, prognostic, or predictive information (47). Concerning the ability for 
diagnosis, a meaningful biomarker should be decisive in an ambiguous histological feature 
or allow a clinically subdivision of tumors from same histological tumor type. A useful 
prognostic biomarker should be able to associate disease-free and overall survival and 
provide information related to the course of the tumors including its recurrence (47, 65). 
Moreover, biomarkers are expected to be predictive, and provide valuable information on 
the response to a given therapy, allowing to catalogue patients into distinct therapeutic 
groups (17, 65). Beyond the above considerations, biomarkers are expected to have high 
specificity and sensitivity and be assessed by simple techniques (17, 47, 65). 
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The following topics are dedicated to the classical biomarkers that are used currently in 
clinical practice for typing and grading oligodendrogliomas, as well as to possible new 
biomarkers that can be used in the study of these glial tumors. 
 
3.2. Classical biomarkers 
 
The first step in glioma diagnosis is to put in evidence structural characteristics of the 
tissue and clarify the origin of glioma, allowing the tumor classification according to cell 
type. In this context, hematoxilin-eosin is used for the first purpose, and GFAP as well as 
Olig2, are used to distinguish between astrocytomas and oligodendrogliomas or even to 
classify oligoastrocytomas. In addition, Ki-67 is an excellent marker to determine the 
growth fraction of a given cell population, and therefore it can be used to measure tumor 
cell proliferation. The evaluation of 1p19q co-deletion, MGMT promoter methylation and 
IDH mutations are considered important clinical biomarkers for diffuse gliomas due to their 
favorable prognostic value. Moreover, protein 53 (p53) is a useful biomarker both for 
diagnostic and prognostic purposes, as it functions as a negative regulator of cell growth. 
Thus, alterations in the p53 gene lead to loss of this negative growth regulation, resulting in 
a more rapid cell proliferation (80). 
As mentioned on subchapter 2.3., other biomarkers can be useful in diagnosis, 
prognosis and as predictive of best-response to a therapy, but some of them are not 
currently used in clinical practice, sometimes due to the difficulty to measure them by 
simple techniques. Thereby, this subchapter will focus only in the ones that are well 
established and are used routinely by medical centers. The differential diagnosis between 
astrocytic and oligodendroglial tumors is truly important to establish prognosis and define 
the therapeutic strategy. Previously, on the glial cells subchapter, we tried to describe 
astrocytes demonstrating their important role in some physiological functions of the brain. 
Here, we intend to enhance GFAP as a marker protein for astrogliosis (16, 17). GFAP, 
firstly reported in 1971 by Eng and his collaborators, is a member of cytoskeleton protein 
family which is increased in CNS injuries, and this increase is proportional to the severity of 
astroglial activation (17).  The function of GFAP is not fully understood but several authors 
indicate its involvement in controlling the shape, movement and function of astrocytes. The 
binding of the GFAP proteins form the intermediate filaments (IF) found in astrocytes (81). 
GFAP apart to have chemical properties and intramolecular polypeptide domains in 
common with others IF, it also has some unique immunogenic epitopes that are detected 
by polyclonal antisera and monoclonal antibodies (81). In order to understand whether 
GFAP could be a useful tool to identify astrocytomas, some studies have been done. The 
   38
results obtained pointed to GFAP as an important biomarker when the origin of the glioma 
is astrocytic. Some studies further try to compare different types of gliomas in which were 
included oligodendrogliomas and oligoastrocytomas. The results were surprising by 
revealing a higher percentage of positive cells in astrocytomas comparing to about half of 
positive cells in pure oligodendrogliomas. Moreover, in oligoastrocytomas the percentage 
of positive cells were found in the astrocytic part. In this perspective, GFAP is a cell-specific 
marker that distinguishes astrocytes from other glial cells (82-84). 
OLIG2 is a member of the Olig family of basic helix-loop-helix (bHLH) transcription 
factors that merits specific mention in this thesis since it plays an essential key in 
oligodendrogliomas identification. During embryonic development of neural cells, the 
expression of Olig2 is found in oligodendrocyte lineage, immature neuronal progenitors, 
and multipotent neuron/glia progenitors. However, in mature cells, the expression is 
restricted to oligodendrocytes, indicating that this transcription factor promotes 
oligodendroglial differentiation and has an additional role in their maintenance (85-87). 
Moreover, studies revealed that in the absence of Olig2, OPC are able to differentiate into 
astrocytes and the expression of this protein is not found in astrocytes of normal healthy 
brain. Besides, expressions of the OLIG2 gene and protein have been found to be highly 
increased in demyelins injury and in human gliomas, specifically those of oligodendroglial 
lineage (85-88). For this reason, Olig2 is proposed to be a diagnostic marker for 
oligodendrogliomas. Despite it seems that the relation between Olig2 and oligodendrocyte 
lineage and differentiation is well established, the truth is that few studies have also 
identified Olig2 in tumors of astrocytic lineage although in a lower expression (85, 89, 90) . 
The Ki-67 protein is the protein of excellence in the determination of tumor biology and 
behavior. The function of Ki-67 in the cell remains unclear but this is not an obstacle to the 
use of this protein as a marker (91). Concerning this, an interesting finding regards the 
presence of this protein in all active phases of a cell cycle (G1, S, G2, M) in contrast with 
quiescent cells (G0) which do not express Ki-67. This fact directly reflects a physiological 
state of the cell which allows to determinate the percentage of proliferating cells (91). The 
excellence of Ki-67 for the diagnosis of cell proliferation is well established between the 
scientific community. However, the same cannot be said regarding its prognostic feature 
even though recent studies demonstrate the possible usefulness of Ki-67 even in 
oligodendrogliomas prognosis. These recent exploratory studies revealed that the 
assessment of Ki-67 index by immunostaining can have a strong prognostic impact as an 
univariable factor showing that patients with a lower Ki-67 value have better favorable 
progression-free survival (92-94). Thus, Ki-67 can be considered a biomarker in evaluation 
of tumor aggressiveness (91). Moreover, since many cytotoxic drugs are aimed to target 
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cell cycle, the assessment of Ki-67 may be an additional prognostic marker in treatment 
protocols.  
The p53 encoded by P53 gene is the most well described tumor suppressor protein. It 
regulates cell cycle progression and apoptosis in response to a wide variety of stress 
signals, including DNA damage. In the presence of genotoxic agents, p53 accumulates in 
the nucleus, binding and regulating the transcription of potential effector genes (95). Many 
studies have been done regarding expression of p53 in tumors, including gliomas, 
revealing an increase of this protein during tumor progression (96).  Furthermore, recent 
studies have revealed that evaluation of p53 expression and 1p/19q mutations improve the 
diagnostic and prognostic evaluation of oligodendrogliomas showing that patients with 
1p/19q loss of heterozygosity and p53-negative expression have a longer progression-free 
survival (97). 
Mutations in P53 are found in more than 50% of all human cancers and, in spite of the 
percentages in gliomas may reach more than 40%, the frequency in oligodendrogliomas is 
much lower (68, 98, 99). Although  the  use of p53 in diagnosis is used worldwide, caution 
is needed in the interpretation of the results since the correlation between gene mutation 
and protein overexpression is not perfect and no direct interpretation can be made between 
overexpression of protein and P53 mutational status (68). 
In spite of the utility of these markers in the classification and grade of 
oligodendrogliomas, all of them have their drawbacks. Moreover, until now, the number of 
markers identified has been limited, the reproducibility between studies is unclear and none 
has been truthfully validated for clinical use (65). In this context, development of objective 
diagnostic, prognostic and predictive markers for gliomas is therefore a priority.  
 
3.3. New glioma biomarkers: exploring cellular and molecular 
changes in gliomas 
 
We believe that exploring new biomarkers for oligodendrogliomas will help to diagnose 
this type of brain tumor in an earlier period, to use target-directed therapies and to better 
monitor the prognosis after treatment (17). 
 
3.3.1. Proliferation and Differentiation  
 
Recently, a population of cells similar to neural stem cells (NSC) in their capacity of 
self-renewal and expression of embryonic stem cells markers have been identified in 
tumors, and named as  cancer stem cells (CSC) (100). The origin of these cells is still 
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under investigation although some hypotheses have been emerged and the most accepted 
refer the fact that CSC can derive from malignization of normal NSC (101). 
Correspondingly, NSC and CSC share common features, such as high proliferation and 
motility, association with blood vessels and white-matter tracks, expression of immature 
antigenic phenotypes and developmental signalling pathways activation (102, 103). 
Moreover CSC seem to be responsible for relapse and resistance of gliomas after 
treatment and their number are related to histological grade of glioma (101, 104, 105). In 
fact, some authors defend that the growth of the tumor is completely dependent of these 
CSC (106). Several studies have been done regarding different proteins involved in the 
regulation of self-renewal capacity. Among these proteins is the SRY (sex determining 
region Y)-box 2 (Sox-2), a critical transcription regulator of embryonic and normal neural 
stem cell function (104, 107). In malignant gliomas, Sox-2 is believed to have a role in 
invasive and migratory skills, increasing the percentage of cells with these potentialities 
(100, 104) and it is also essential for maintaining the self-renewal and multipotency of NSC 
(108, 109). Several malignancies have demonstrated evident alterations in Sox-2 
expression, mainly its overexpression, such as in glioblastomas (110-115). Regarding 
oligodendrogliomas, and although only a few studies have been done, the finding indicated 
that Sox-2 is up-regulated in the most anaplastic areas of oligodendrogliomas (116). These 
interesting data prompted us to further investigate the expression of Sox-2 in our 
oligodendroglioma cases. 
In 1990, a new conception has emerged regarding neurogenesis in the adult brain. 
Until there, scientific community believed that neurogenesis occurred during the embryonic 
development; however, several studies reported that in particular areas of adult human 
brain, neurogenesis can occur. This continuous process is sustained by NCS, a class of 
cells capable of self-renewing, which can give rise to different neural lineages such as 
neurons, astrocytes and oligodendrocytes. The discovery of this cellular population in adult 
human brain paved the way for several enthusiastic studies. Researchers quickly realized 
that embryonic neurogenesis and adult neurogenesis present some differences, particularly 
regarding location and frequency. To date, it is accepted that adult NSC are restricted to 
niches mostly located in the subventricular zone (SVZ) and hippocampal subgranular 
zones (SGZ) and the frequency by which neurogenesis occurs is much lower and under 
tight regulation (117). However, it is consensual between researchers that the 
understanding about this class of cells could help in the development of new therapies and 
different strategies to be used in CNS injuries.  
In the sequence of NSC knowledge a recent population of cells was described 
expressing the transmembrane NG2. They are mostly referred as oligodendrocyte 
progenitor cells (OPCs/NG2 cells) due to their ability to differentiate into oligodendrocytes. 
 Some studies point that NG2 
progenitor cells. Recently it was indicated its ability
76). Few studies have related NG2+ cells with brain injuries. It is believed that this protein 
is expressed on perivascular and
that it has a role in the establishment of cellular extensions, which a
polarity during morphogenesis or migration
cells are believed to have a role in cell adhesion, migration and invasion.
Recent findings suggest that over
increased proliferation and growth indicating a poor survival outcome. In relation with this
increased, we thought that NG2 could be an excellent preliminary marker to
in oligodendrogliomas. In fact, it was recently suggested that transformed multipotent NG2 
glial precursor cell may be a potential cell 
induced oligodendroglioma-
differentiation into oligodendrocytes.
 
Fig. I.12 - NSC differentiation into oligodendrocytes.
expressed. As cells differentiate from NSCs to neural progenitor cells, 
expression in order to differentiate.
early oligodendrocyte biomarker.
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3.3.2. Adherens junctions  
 
Adherens junctions (AJ) are composed by transmembrane glycoproteins of the 
cadherin super family, which form adhesive complexes with neighboring cells. AJ mediate 
several events including regulation of paracellular permeability (119). The cell-to-cell 
adhesion is made by linking actin-based cytoskeleton which involves vascular endothelial 
(VE)-cadherin and catenins (Fig. I.13) (12, 120). The association of VE-cadherin and their 
intracellular structural catenin form a complex of relevant importance in maintaining the 
integrity of adult tissue (12, 121-123). In this context, E-cadherin and β-catenin, as a 
complex, are specifically involved in the regulation of epithelial cell-to-cell adhesion and 
they appear to be strongly related with the invasion and metastasis ability of cancer (124). 
In addition, catenins can also participate in cell signaling pathways, such as the Wingless 
(Wnt) signalling pathway (12). In the Wnt signalling pathway, β-catenin regulates a variety 
of cellular processes since it acts as a major transcriptional modulator for the regulation of 
Wnt/β-catenin targets and plays a crucial role in embryogenesis, stem cell renewal and 
organ regeneration (122, 123, 125). Due to its importance in cell signalling, several studies 
have demonstrated that imbalance in β-catenin expression and activity can induce 
malignant pathways in normal cells (122, 126). In fact, upon stimulation with growth factors, 
the dissociation of the complex between VE-cadherin and β-catenin may occur. 
Consequently, the loss of the complex is an advantage for tumor cells, as it will breaks the 
adherens junctions and the separation between adjacent cells, increasing their invasive 
and metastasis capacities (123, 126). On the other hand the accumulation of β-catenin 
itself can act as an oncogene, modulating the transcription of different genes inducing 
cancer initiation, progression, survival and relapse, and thus, it might be related with 
tumorigenesis (122, 123, 125). This raises the possibility that β-catenin may constitute a 
relevant target for therapeutic strategies that can act on its degradation or inactivation (122, 
123, 127). Studies performed in gliomas showed that β-catenin is upregulated in most 
malignant forms of gliomas predicting a worst outcome survival (128). 
 
  
Fig. I.13 - β-catenin intracellular localization
of the adherens junctions between VE
interaction of VE-cadherin with the actin
Upon stimulation, the dissociation of the complex with VE
endothelial barrier became compromised. Wnt inhibits the degradation of 
translocated into the nucleus leading to changes in different target gene expressio
with cell cycle progression. Adapted from
 
3.3.3. Transcellular pathway across endothelial cells
 
Passage of molecules across the endothelial cells can occur between adjacent cells 
(paracellular pathway) or through the cells (transcellular pathway) 
importance of both pathways for transendothelial permeability, we will just considerer the 
transcellular pathway. This pathway involves several different mechanisms inclu
passage from transport proteins such as caveolins.  Caveolins consist of a family of three 
proteins in which one of the most important is caveolin
plasma membrane and is involved in various aspects of vesicular traf
transduction pathways. Concerning vesicular trafficking, caveolin
for the formation of caveolae. Caveolae are structural and functional invaginations of the 
plasma membrane rich in small glycolipids and cholestero
trafficking, caveole seems to be essential for endocytosis, lipid homeostasis and signaling 
processes (131).  
Caveolin-1 in endothelial cells is involved in regulation of angiogenesis, 
microvascular permeability and vascular remodeling but also takes part in other 
pathophysiological processes such as oncogenic transformation. 
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Fig. I.14 - Schematic diagram of the role of c
are invaginations of the plasma membrane in which c
acting as a scaffolding protein to regulate signaling molecules
cell. Adapted from Schnitzer (2001)
 
3.3.4. Autophagy
 
Autophagy is an essential cellular mechanism that controls obsolete or non
functioning organelles inside the cells. This phenomenon is known as being extremely 
regulated but not completely understood. Evidences have demonstrated that a double 
membrane of unknown origin encloses the components to be destroyed, forming a vesicle 
called autophagosome. Then the autophagosome fuses with a lysosome to form 
autolysosomes which are degraded by lysosomal
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This mechanism is also important for the maintenance and viability of the cells 
during stress conditions allowing them to survive by providing energy substrates, 
moderating accumulation of reactive oxygen species (ROS) and reducing the damaged 
components within the cell (136). Cancer cells compared to normal ones usually need 
additional nutrition to produce proteins and enzymes for their faster proliferation. In this 
way, autophagy can be an advantage for cancer cells allowing them to have more 
sustenance for their growth (138). This fact can be an obstacle in tumor treatment since 
several drugs lead to nutrient and oxygen supply. Furthermore, some authors described 
that in early or later stages of tumor progression, autophagy is activated in stressed tumor 
regions (139, 140). For this reason, many studies have been done in order to inhibit the 
autophagy process to enhance the therapeutic efficacy of these drugs (136).  
The proteins involved in the regulation of autophagy were first identified in yeasts 
but have demonstrated to be homologues to the ones in higher eukaryotes (136, 137). 
Among them, LC3 (Light Chain 3) is a microtubule-associated protein and is one of the 
most essential proteins in autophagy being crucial in the formation of autophagosomes 
(Fig. I.15) (137). Regarding the function of LC3 in the autophagosome, it has been shown 
that this protein can select cargo for degradation but it also promotes fusion of other 
membrane compartments like endosomes or mitochondria (137, 141). 
Based on the importance of LC3 and the fact that it is one of the most described 
specific proteins for autophagy, LC3 is commonly used as a biomarker of autophagy. 
Regarding cancer biology, its association with tumors has been studied by several 
researchers but few studies have been done regarding oligodendrogliomas. Since this 
thesis aimed to evaluate possible new biomarkers, LC3 was thought to be one of the most 
promising biomarkers to evaluate. Recent studies revealed that cancer cells that express 
lower levels of LC3 (140, 142, 143) are associated with a more aggressive form of tumor 
(140, 144, 145). In contrast, others have demonstrated an increased LC3 expression and 
also variations associated to tumor type (146, 147). Concerning gliomas, a recent study 
with glioma cell lines demonstrated that LC3 expression was upregulated in gliomas 
treated with temozolamide and that such increase possibly relates with chemoresistance 
and consequently to a more malignant form of cancer (147). Thus, the lack of studies 
regarding the expression of this marker in oligodendrogliomas and some existing 
contradictory results encouraged us to further investigate whether LC3 could be a possible 
advantageous biomarker in this type of cancer. 
 
 Fig. I.15 - Schematic diagram of the role of 
enclosing the components to be destroyed. Then LC3 protein 
autophagosome is formed. Subsequently
generates the autolysosome.   
 
3.3.5. Neuronal cytoskeleton
 
NFs are IF that, together with microfilaments and microtubules form the
cytoskeleton (148). In immunohistochemical pathology, IF typing is an advantageous tool in 
the characterization of tumors. In CNS, the major neuronal IFs are the neurofilament triplet 
proteins (NFTPs) and α-internexin. NFTPs consist on three subunits of different weights: 
NFL, NFM and NFH (low, medium and high
NFs are mostly present in m
of axon caliber and transmission of electrical impulses 
 NFs have been used as hallmarks of a number of different diseases and the levels 
of expression could be helpful
almost all of neurodegenerative disease
proteins in CNS. Although in immunohistochemical pathology, IF typing is an advantageous 
tool in the characterization of tumors, few studies have 
reason, we were interested in studying NFs in oligodendrogliomas
value as a promising biomarker
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3.3.6. Microvasculature changes 
 
Gliomas show increased vascular proliferation which seems to be correlated with 
the different glioma degrees (76, 150). Vascular proliferation increases blood supply, 
feeding the tumor with oxygen and nutrients essential for tumor growth. By this reason, 
experts in oncology believe that tumor growth is dependent on angiogenesis. Moreover, 
increase of microvasculature allows the progression of the tumor since it permits the 
migration of tumor cells and consequently installation of these cells in native tissues, 
spreading tumors to other organs (151). Thus, the vascular proliferation appears to be one 
of the major determinant features in tumor pathophysiology (150). This process involves 
cellular communications, providing cell adherence and migration through vessels (Fig I.16), 
promoting invasion and possible metastasis (152). In tumors, blood vessels have abnormal 
physiology, such as irregular size and shape and normally present defective intercellular 
gaps. These defects in endothelial cell barrier function are related with vascular leakiness, 
active angiogenesis and microvascular remodelling (153). In addition, tumor vessels 
express molecules which may serve as targets for therapeutic agents (154). One of the 
most potential markers for vascular proliferation is CD31. CD31, also designated as 
PECAM-1 (platelet endothelial cell adhesion molecule 1), is a transmembrane glycoprotein 
and member of the immunoglobulin superfamily (155-157). It is the first element of the 
endothelial intercellular junction which play a role in leukocyte extravasation by facilitating 
leucocyte migration between endothelial cells during inflammation (155, 157, 158). CD31 
has recently been recognized for its various roles in biologic functions including 
angiogenesis, apoptosis, platelet aggregation and thrombosis (155). Due to its 
characteristics, it is one of the best markers for benign and malignant vascular tumors (155, 
157, 159, 160). Studies in gliomas have demonstrated that vascular density is inversely 
correlated with time survival which is related to a worst prognostic (161-164). Although 
there are few studies regarding CD31 expression in oligodendrogliomas, there is one that 
has demonstrated that oligodendrogliomas appear to have a lower microvascular 
proliferation and density as compared with the other glioma types (162). 
 
 
 Fig. I.16 - Glioma cells and their relationship and interdependence with cerebral vasculature. 
Glioma cells release molecules 
growth (b). The tumor cells preferentially migrate and invade along the ablum
vasculature. Adapted from Rowinsky (2002)
 
A further determinant 
of pericytes. As described before, perycites are tighly connected with endothelial cells 
giving stability to vessel walls and allowing regulation of blood flow in the microcirculation. 
Modifications on endothelial cells lead to loss of pericyte association and alterations in 
shape and cytoplasmic projections into the tumor parenchyma
increases vascular permeability and makes 
an obstacle to therapy (166)
ranges from extensive to little or none 
that the most malignant forms of gliomas 
vascular environment, thus increasing tumor progression 
studies regarding oligodendrogliomas. Therefore
in our study could bring us relevant 
type of brain tumor. 
 
3.3.7. Drug resistance
 
Despite all the advances in developing novel therapeutic strategies, the multidrug 
resistance (MDR) phenomenon is an important feature to consider during brain tumor 
research. MDR is defined as the lack of sensitivity of malignant tumor cells to different 
anticancer drugs, whose structures and mechanism of action may be different 
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phenomenon can represent a serious obstacle in cancer therapy. The mechanisms by 
which MDR can interfere are classified into four different categories: i) enhanced drug 
efflux pump activity; ii) modulation of cell death pathways; iii) alterations and repair of drug-
targeted molecules; and iv) acceleration of drug modification by drug metabolizing 
enzymes (169). The present work is concerned only about the first category in which MDR 
is associated with the efflux activity of some proteins. Among these proteins is P-
glycoprotein (P-gp). P-gp was the first member of ABC transporter family to be identified 
and seems to modify membrane permeability to several lipophilic anticancer drugs being 
the mostly frequent transporter to be related with MDR (169). In normal conditions, P-gp 
can be an important mechanism in defending cells by protecting them from endogenous 
and exogenous substances. Moreover, it appears to play a role in cell differentiation, 
proliferation, immune responses and apoptosis (170). However, this mechanism of defence 
can be deleterious when talking about drug delivery, since it may severely restrict the 
arrival of drugs into brain parenchyma. The localization of P-gp in the BBB has been 
demonstrated to be at the luminal (apical) membrane of brain capillary endothelial cells, 
mediating an active extrusion of their substrates into the blood. Consequently, the net 
penetration of drugs from the blood into the brain is remarkably modulated by this 
transporter (171). Moreover,  there are some studies suggesting that P-gp is located at the 
astrocyte end-feet processes ensheating brain capillaries (172). This transporter was also 
demonstrated to be expressed in injured neurons and microglia (173). 
The strong clinical impact of MDR in cancer therapy, led to multivariate studies about 
the mechanisms and processes to modulate this pathway. In this regard, several 
compounds that interact with P-gp and consequently block drug efflux have been reported 
to reverse MDR (Fig.I.17) (174). 
The study of P-gp expression in gliomas did not reveal to have a significant impact. In 
fact, the few studies elaborated in this context have not shown any correlation of this 
marker in gliomas with controls (175). However, some studies showed that P-gp 
expression differs among the different grades of glioma, being increased in higher grade 
ones (176-178).  
 Fig. I.17 - Schematic diagram of the role of P
drugs migrate along the vasculature
gp pump permits the exit of the drugs from the
presence of a P-gp inhibitor, drugs cannot leave the cells which increase their therapeutic 
Adapted from Drug development technology (2012)
 
4. Aims 
 
The general goal of this work 
anaplastic oligodendroglioma
be of a great benefit not only to the patients but also to clinicians, 
reliable and objective decisions regarding dia
appropriate therapy. 
To accomplish this aim, human paraffin
from patients with oligodendrogliomas
immunocytochemistry in order to (i) quantify 
with proliferation and differentiation processes (Sox
endocytosis (caveolin-1), signal transduction
microvasculature changes (CD31, 
Afterwards, based on the data obtained we will (ii) compare the expression of these 
proteins in the different oligodendrogliomas grades. Finally, we expect to be able to (iii) 
identify the most promising candidate
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II. Material and Methods 
5. Ethics Statement 
 
This work has been approved by the ethical committees at the Laboratory of 
Neuropathology, Department of Neurology, Hospital de Santa Maria, as well as at the 
Department of Neurology, Instituto Português de Oncologia de Lisboa. 
 
6. Reagents and antibodies 
 
Bovine serum albumin (BSA) was acquired from Sigma (St Louis, MO, USA); Triton X-
100 was obtained from Roche Diagnostics (Germany) and p-Xylene-Bis-Pyridinium 
Bromide (DPX) mountant for microscopy was purchased from BDH Prolabo (Poole, UK). 
Rabbit anti-Sox-2 (#sc-20088) was purchased from Santa Cruz Biotechnology (CA, USA); 
rabbit anti-NG2 (#AB5320) from Millipore (Temecula, CA, USA); mouse anti-β-catenin 
(#138400) was obtained from Invitrogen (Carlsbad, CA, USA); rabbit anti-caveolin-1 
(3238S) and rabbit anti-LC3 (#2775S) and were acquired from Cell Signaling (Danvers, 
MA, USA); rabbit anti-CD31 (#ab28364) were acquired from Abcam (Cambridge, UK). 
Mouse anti-NF (NF160) was obtained from Novocastra (Newcastle, UK); mouse anti-α-
actin (#A5228) was purchased from Sigma and mouse anti-P-gp (#517310) from Merck 
(Nottingham, UK). Secondary antibodies goat anti-rabbit coupled to Alexa Fluor® 488 
(#A11008) and goat anti-mouse coupled to Alexa Fluor® 594 (#A11005) were obtained 
from Invitrogen. 
7. Clinical data collection 
 
Formalin-fixed, paraffin-embedded samples from four different normal brain and nine 
gliomas (oligodendrogliomas) were retrieved from the Laboratory of Neuropathology, 
Department of Neurology, Hospital de Santa Maria, as well as from the Department of 
Neurology, Instituto Português de Oncologia de Lisboa (Table II.1). These cases were from 
8 females and five males with age raging from 17 to 78 years-old. The specimens had 
confirmed non-neoplastic tissue (controls) or pathological diagnosis and the last were 
classified according to the WHO criteria patients.  
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Table II.1 – Clinical data of control and neoplastic samples 1 
Diagnosis Sample  
source 
Gender Age Average Age Tumor localization 
Control HSM 
Male n = 1 25 
27 
Occipital Lobe 
Female n = 3 
46 Right Temporal lobe 
21 
Fronto-temporal 
insular lobe 
17 Left frontal lobe 
Grade I IPO 
Male n = 1 54 
59 
Left temporal lobe 
Frontal lobe 
Female n = 1 63 Left temporal lobe 
Grade II HSM 
Male n = 1‡ 38 
37 
Right frontal insular 
lobe 
Female n = 2‡ ‡ 
35 
Left fronto-temporal 
insular lobe 
35 
Left fronto-temporal 
insular lobe 
Grade III 
IPO 
 
HSM 
Male n = 1 78 
67 
Left temporal lobe 
Female n = 2 
51 Left frontal lobe 
72 Right temporal lobe 
 
HSM – Hospital de Santa Maria; IPO – Instituto Português de Oncologia 
8. Immunofluorescent staining method 
 
For immunostaining, 3 µm sections were deparaffinized in 100% xylene during 10 
minutes and hydrated in descending ethanol series from 100% to 70% and water for 10 
minutes each. Heat-induced antigen retrieval was performed in 37.2 mM citrate buffer for 
20 min at 50ºC and afterwards for 10 min at 80ºC. Then, sections were placed 3 times in 
PBS buffer during 10 minutes. Samples were incubated in a humidified chamber overnight 
                                                 
1
 Concerning patient therapies when samples were collected we cannot add the specific regiment 
that patients were submitted to. However for a few patients we got the following information: ‡ 
combined therapy of 5-Fluorouracil, CCNU and vincristine; ‡ ‡ radiotherapy after surgery. 
 at 4ºC with primary antibody diluted in accordance with T
in 3% BSA+ 0,1% Triton X
overnight at 4ºC with antibodies 
goat anti-mouse coupled to Alexa
The next day, DAPI was added diluted in PBS (1:2500) during 10 minutes at room 
temperature and washed with PBS. The samples were then dehydrated in ascending 
ethanol series (70%, 96% and 100%) for 10 minutes each, drie
xylene during 10 minutes. Finally
 
Table II.2 – List of antibodies used for immunohistochemistry
Markers Sox-2 NG2 
Host 
Species 
Rabbit Rabbit 
Dilutions 1:250 1:150 
 
Tissue sections were visualized in a 
Germany) with integrated camera (AxioCamHRm). 
immunohistochemistry staining
 
Fig. II.1 - Simple preparation 
retrieval was performed and (C) samples were incubated overnight with primary antibody and then 
incubated overnight with a secondary antibo
dehydrated and (E) mounted to analyze in a microscope.
 
9. Evaluation of cellular biomarkers
 
In order to compare the cellular behavio
neoplastic tissue and in the different
for different cellular biomarkers, as mentioned in the previous section 
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able II.2. The antibody was diluted 
-100. After washing 3 times in PBS, sections were incubated 
goat anti-rabbit coupled to Alexa Fluor
 Fluor® 594 (1:1000) in 3% BSA + 0,1% Triton X
d and emerged in 100% 
 were dried and mounted with DPX.  
 and their dilutions
β-
catenin 
Caveolin-
1 
LC3 NF CD31
Mouse Rabbit Rabbit Mouse Rabbit
1:125 1:125 1:100 1:50 1:100
fluorescence AxioScope.A1 microscope, (Zeiss, 
Figure II.1 resumes schematically the 
 procedure. 
scheme. (A) Samples were deparaffinized; (B) heat
dy, followed by DAPI addition. (D) Samples were 
 
 
r and the environmental changes in non
 grades of oligodendroglioma, sections were stained
(Table II.2
 
® 488 (1:1000) or 
-100. 
. 
 
α-
actin 
P-gp 
 Mouse Mouse 
 1:250 1:100 
 
-induced antigen 
-
 
). 
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 To evaluate cell proliferation, differentiation and autophagy, immune-positive cells and 
total cells of ten random microscopic fields were counted to determine the percentage of 
Sox-2- NG2- and LC3-positive nuclei, respectively. The resultant values were presented as 
percentage of positive cells for each staining. 
Regarding the evaluation of cell adhesion, transcellular transport, neuronal 
cytoskeleton, microvasculature changes and drug resistance, the percentages of β-catenin, 
caveolin-1, NF, CD31 and α-actin, as well as of P-gp, respectively, were measured in ten 
random microscopic fields. For each biomarker, ImageJ software was used to define the 
threshold value for background correction and the integrated density was measured. This 
measure is the area above the threshold for the mean density minus the background. 
Table II.3 resumes the biomarkers used in this study as well as the chosen 
quantification method. 
 
Table II.3 – Biomarkers used to evaluate specific cellular molecular changes and respective 
quantification method. 
 
Markers Cellular/Molecular changes Quantification 
 
LC3 
Autophagy Positive Cells (%) 
NF 
Neuronal 
cytoskeleton 
Integrated 
density 
P-gp 
Drug 
resistance 
Integrated 
density 
CD31 
Microvasculature 
changes 
Integrated 
density 
α-actin 
Microvasculature 
changes 
Integrated 
density 
 
Sox-2 
Proliferation Positive Cells (%) 
β-catenin Adherens junctions Integrated 
density 
Caveolin-1 Transcellular transport 
Integrated 
density 
NG2 Differentiation Positive Cells (%) 
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10. Statistical analysis 
 
All results were expressed as mean ± SEM. Significant differences between two groups 
were determined by the two-tailed t-test performed on the basis of equal or unequal 
variance as appropriate, and the P-value of P<0.05 was considered as statistically 
significant. 
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III. Results 
 
1. Immunofluorescence analysis of cell proliferation  
 
To determine cell proliferation, samples were stained with Sox-2, a neural stem cell 
marker (Fig. III.1). Evaluation of the number of Sox-2-positive cells revealed that this 
protein is highly expressed in all the glioma grades as compared to control samples 
(P<0.05 for grade I, P<0.01 for grades II and III). Moreover, we have observed that there 
was a gradual increase in Sox-2 positive (P≤0.05) cells from grade I (26% Sox-2 positive 
cells) to grade III (38% Sox-2 positive cells). These results indicate a higher proliferative 
potential in oligodendrogliomas that seems to be correlated with the grade aggressiveness, 
with the grade III showing significance with the grade II (P<0.05).  
 
 
2. Immunofluorescence analysis of cell differentiation  
 
Our human samples were also stained for NG2, a marker of oligodendroglial progenitor 
cells.  As seen in Fig. III.2, all the oligodendroglioma samples evidenced a higher number 
of NG2-positive cells as compared to controls (P<0.01). Although there was an increase in 
NG2 expression along the tumor grades (from 28% NG2 positive cells in grade I to 37% 
NG2 positive cells in grade III), the difference between grades was not statistical 
significant, suggesting that this marker may have diagnostic value, but only to distinguish 
between healthy and pathological brain tissue, once do not differentiate oligodendroglioma 
grades. 
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Fig. III.1 – Expression of Sox-2, a neural stem cell marker, in healthy (control) and neoplastic 
samples (oligodendroglioma grade I, II and III). A) Representative results of one experiment. 
Brain sections were immunolabeled for Sox-2 (green) and nuclei were counterstained with DAPI dye 
(blue). Original magnification 400x. B) Graph bars represent the percentage of cells (mean ± SEM) 
positive for Sox-2, relatively to the total number of nuclei. *P<0.05 and **P<0.01 vs. control samples; 
#P<0.05 vs. the immediate lower glioma degree.  
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Fig. III.2 – Expression of NG-2, an oligodendrocyte progenitor cell marker, in healthy (control) 
and neoplastic samples (oligodendroglioma grade I, II and III). A) Representative results of one 
experiment. Brain sections were immunolabeled for NG-2 (green) and nuclei were counterstained 
with DAPI dye (blue). Original magnification 400x. B) Graph bars represent the percentage of cells 
(mean ± SEM) positive for NG2, relatively to the total number of nuclei. **P<0.01 vs. control 
samples. 
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3. Immunofluorescence analysis of cell adhesion  
 
Cell-cell adhesion plays an important role in tissue morphogenesis and homeostasis 
and is commonly mediated by the cadherin-catenin complex (180). In order to evaluate cell 
adhesion properties, human samples were stained for β-catenin. Results show that there is 
a lower β-catenin expression in oligodendrogliomas of grade II and III, as compared to 
control samples (Fig. III.3), which is only significant in the most aggressive type (0.2-fold 
decrease from control, P<0.05). Thus, although additional experiments are needed to 
confirm these results, it seems that cell adhesion may be lost in the most invasive types of 
oligodendrogliomas, as it was expected. 
 
When cells start to establish cell-cell contacts, caveolin-1 redistributes and localizes in 
those areas. These observations may be related to the possibility that caveolin-1 is 
involved in regulating cell adhesion-mediated processes. Thus, we have then evaluated 
caveolin-1 in both control and neoplastic samples and observed that oligodendrogliomas 
show an increase of this marker as compared to control samples (Fig. III.4). However, this 
higher expression was only significant for grade II gliomas (2-fold increase, P<0.05). 
Interestingly, these results also revealed a gradual decrease in caveolin-1 expression from 
grade I to grade III tumors, although no significance was founded. As for β-catenin the 
variation we have encountered indicate that a higher number of cases should be evaluated 
to better decide on the value of this biomarker for oligodendroglioma grading. 
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Fig. III.3 –  Expression of β-catenin, a regulator of cellular adhesion, in healthy (control) and 
neoplastic samples (oligodendroglioma grade I, II and III). A) Representative results of one 
experiment. Brain sections were immunolabeled for β-catenin (red) and nuclei were counterstained 
with DAPI dye (blue). Original magnification 630x. B) Graph bars represent the integrated density 
(mean ± SEM) with respect to β-catenin staining. *P<0.05 vs. control samples.  
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Fig. III.4 –  Expression of caveolin-1, a major component of caveolae, in healthy (control) and 
neoplastic samples (oligodendroglioma grade I, II and III). A) Representative results of one 
experiment. Brain sections were immunolabeled for caveolin-1 (green) and nuclei were 
counterstained with DAPI dye (blue). Original magnification 630x. B) Graph bars represent the 
integrated density (mean ± SEM) with respect to caveolin-1 staining. *P<0.05 vs. control samples.  
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4. Immunofluorescence analysis of autophagy 
 
To assess cell autophagy, human samples were stained for LC3, an autophagic 
marker.  As seen in Fig III.5, results clearly show an increase in LC3 positive cells from 
control (15%) to oligodendroglioma samples (18%, 22% and 25%, for grades I, II and III, 
respectively) but this was only statistically significant for grade III (P<0.01). These results 
suggest that LC3 could be considered a good biomarker for the diagnosis of the most 
aggressive type of oligodendroglioma. 
 
5. Immunofluorescence analysis of neuronal cytoskeleton 
 
Due to insufficient immunostaining and/or tissue quality, assessment of NF was very 
difficult to obtain in all samples. Thus, for this evaluation we considered to be assessable 2 
samples of controls, 1 sample of grades I and II and 3 samples of oligodendroglioma grade 
III. Although further assessments are nedded, we can observe in Fig. III.6, that there is a 
strong staining for NF in oligodendroglioma grade III samples (9-fold increase from control, 
P<0.01), suggesting that this may be a promising biomarker for this type of brain tumor. 
Only further studies with a higher number of cases or alternative staining may help in such 
conclusion. In addition, significance of this increased NF staining deserves to be explored 
in the future.  
 
6. Immunofluorescence analysis of microvasculature changes 
 
To characterize microvasculature structure, we have incubated tissues with an antibody 
against CD31, which stains brain vessels. The results (Fig. III.7) demonstrate that 
expression of CD31 increases with oligodendroglioma grading from 1.1 in grade I, to 1.3 in 
grade II and 1.6 in grade III. These results indicate that CD31 may be considered a good 
biomarker for the most aggressive type of oligodendrogliomas. Again, and as previously 
observed for NF, LC3, NG2 and Sox-2, higher values were noticed in the grade III 
(P<0.05). 
 
As described in the introduction section, pericytes are tighly connected with endothelial 
cells, and thus, the presence of these cells, which stain for  α-actin, is a further determinant 
fact regarding microvasculature changes. Our results regarding α-actin labelling in our 
human samples (Fig. III.8) showed a great decrease in the expression of this protein in 
gliomas as compared with controls (0.2-, 0.5- and 0.3-fold changes for grade I, II and III, 
respectively; P<0.01 for grades I and III). Interestingly, it seems that the less malignant 
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glioma type is the one where there is the highest decrease on pericyte density, but this fact 
needs to be further explored by analysing a higher number of tissue samples. It would be 
interesting to explore whether this finding is related with the increased angiogenesis of the 
tumor. 
 
7. Immunofluorescence analysis of drug resistance 
 
As in some of the previous parameters, we also had some difficulties in the optimization 
of P-gp staining and its evaluation. Thus, it was only possible to consider 1 sample by each 
group. Although very preliminary, the results suggest that there is an increase in the 
expression of this efflux transporter for all grades of gliomas comparing to the control 
group. Unfortunately, despite these promising results, the lack of samples did not allow to 
determine any statistical significance. Nevertheless, it seems that all the oligodendroglioma 
samples are associated with a multidrug resistance phenotype, as it was expected (Fig. 
III.9).  
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Fig. III.5 –  Expression of LC3, an autophagic cell marker, in healthy (control) and neoplastic 
samples (oligodendroglioma grade I, II and III). A) Representative results of one experiment. 
Brain sections were immunolabeled for LC3 (green) and nuclei were counterstained with DAPI dye 
(blue). Original magnification 630x. B) Graph bars represent the percentage of cells (mean ± SEM) 
positive for LC3, relatively to the total number of nuclei. **P<0.01 vs. control samples.  
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Fig. III.6 –  Expression of NF, a neuronal cytoskeleton marker, in healthy (control) and 
neoplastic samples (oligodendroglioma grade I, II and III). A) Representative results of one 
experiment. Brain sections were immunolabeled for NF (red) and nuclei were counterstained with 
DAPI dye (blue). Original magnification 630x. B) Graph bars represent the integrated density (mean 
± SEM) with respect to NF staining. **P<0.01 vs. control samples. 
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Fig. III.7 – Expression of CD31, a marker for microvasculature, in healthy (control) and 
neoplastic samples (oligodendroglioma grade I, II and III). A) Representative results of one 
experiment. Brain sections were immunolabeled for CD31 (green) and nuclei were counterstained 
with DAPI dye (blue). Original magnification 400x. B) Graph bars represent the integrated density 
(mean ± SEM) with respect to CD31 staining. *P<0.05 vs. control samples. 
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Fig. III.8 – Expression of α-actin, a pericyte cell marker, in healthy (control) and neoplastic 
samples (oligodendroglioma grade I, II and III). A) Representative results of one experiment. 
Brain sections were immunolabeled for α-actin (red) and nuclei were counterstained with DAPI dye 
(blue). Original magnification 630x. B) Graph bars represent the integrated density (mean ± SEM) 
with respect to α-actin staining. **P<0.01 vs. control samples.  
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Fig. III.9 – Expression of P-gp, a marker for multidrug resistance, in healthy (control) and 
neoplastic samples (oligodendroglioma grade I, II and III). A) Representative results of one 
experiment. Brain sections were immunolabeled for P-gp (red) and nuclei were counterstained with 
DAPI dye (blue). Original magnification 630x. B) Graph bars represent the integrated density (mean) 
with respect to P-gp staining. 
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IV. Discussion 
 
The pathological evaluation and subtyping of gliomas can be very challenging. Several 
studies have been done with the purpose of helping in the diagnosis, prognosis and 
therapeutics of these brain tumors. However, clinical evaluation can still be a dilemma. In 
this regard, the present study was undertaken to assess nine different possible biomarkers 
involved in cellular proliferation and differentiation, cell adhesion, autophagy, neuronal 
cytoskeleton, microvasculature changes and drug-resistance properties.  
 Gliomas consist of a heterogenous mixture of several glial phenotypes, composed 
by immature cell types, poorly differentiated neoplastic glial cells and mature cells. Some 
controversy still exists in turn of the origin of these brain tumors, once some authors refer 
to NSC as the cells that undergo molecular and cellular transformation that can lead to 
tumoral growth, while others think that glioma arises from dedifferentiation of mature glia 
(76, 103, 181). However, the last hypothesis has been increasingly discarded, and 
according to some recent works, modifications in the normal glial NPC differentiation can 
lead to the generation of abnormal cells, instead of mature astrocytes (or oligodendrocytes, 
in the case of oligodendrogliomas). This hypothesis for glioma origin has been explored 
because NSC and NPC share some features with gliomas, such as the expression of 
undifferentiated or progenitor cell markers. 
Thus, we first evaluated the expression of Sox-2, which is a neural stem cell 
marker, in order to investigate the proliferative potential of our neoplastic samples, as 
compared with controls. We have identified a population of Sox-2 positive cells with a 
strong capacity of proliferation, which increases with the aggressiveness of the tumor. 
These results are in agreement with several studies that indicate an active role for Sox-2 in 
tumor development (182, 183). Interestingly, the expression of Sox-2 has been associated 
to CSC which are described by some authors as the responsible for sustaining tumor 
growth, as well as relapse and resistance of gliomas (105). Our results support these 
findings, suggesting that Sox-2 is related with the malignant progression of 
oligodendrogliomas and that this transcription factor could be crucial in the progression of 
grade II to grade III oligodendroglioma. Moreover, being Sox-2 a persistent marker that 
regulates self-renewal, the presence of this marker in CSC population can probably be 
another promising marker not only for diagnosis but also as a prognostic biomarker. In fact, 
conventional therapies aim to destroy tumor and non-tumor cells, but they spare the 
subpopulation of brain CSC, which eventually regenerate the tumor. By showing an 
increase in this stem cell population along the tumor grades, our results support the need 
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of adjuvant therapies for brain tumor treatment targeted towards CSC, as a way to improve 
therapeutic efficacy and reduce tumor recurrence. 
The expression of NG2 is related with the presence of progenitor cells of 
oligodendrocyte lineage. By using NG2 as a biomarker, we identify an oligodendroglioma 
cell population that is still very immature and that may be responsible for tumor growth. In 
the present work our results indicate that the increase in NG2 expression is clearly visible 
in all oligodendrogliomas, as compared with controls. Even more, we demonstrate that the 
expression of NG2 is gradually increasing along tumor grading increase. In fact, some 
studies describe that, in response to various chemical, immunological and traumatic 
injuries, oligodendrocytes are repopulated to restore the damage and eventually to 
replenishing cellular deficit in myelination (184-186). Our results are supported by several 
studies in which authors have also observed an increase in NG2 positive cells in most 
malignant forms of brain tumors (187, 188).  
Correspondingly, the most malignant form of glioma, which is glioblastoma, 
evidence higher levels of NG2 as compared to less aggressive tumors (188-190). This led 
us to hypothesize that not only in astrocytomas, as purpose by others, but also in 
oligodendrogliomas, as observed by us, the NG2 biomarker seems to be very useful for 
diagnosis. Overall, we can conclude that due to the high  expression of NG2 in the most 
aggressive forms of oligodendrogliomas, as well as its location (on cell surfaces), NG2 
positive cells can be considered as potential therapeutic targets in tumor treatment. 
 To better evaluate the relevance of adherens junctions in oligodendrogliomas, we 
have incubated our human samples with an antibody raised against β-catenin. Our findings 
were surprising since the decrease of the expression of this marker was particularly evident 
in the most aggressive form of oligodendrogliomas. However, most of the studies that 
investigate the role of β-catenin signaling on gliomas, mainly performed in astrocytomas 
demonstrated that its expression is higher in glioma patients than normal controls and 
significantly increases with the histological astrocytoma grade (191, 192).  
Results here presented are consistent with some other studies which reveal that the 
β-catenin signaling can involve different proteins in which some pathways lead to a 
decrease of β-catenin expression (193-195). Accordingly, the downregulation of β-catenin 
leads to a decrease of complexes with VE-cadherin (196). Indeed, the dissociation of this 
complex dismantled normal adhesive function by increasing paracellular permeability and 
facilitating the cross of several components which in normal conditions were not able to 
access the brain parenchyma (197). In this way, we may hypothesize that in the most 
aggressive forms of oligodendrogliomas, the decrease in β-catenin expression may 
correspond to a mechanism by which cancer cells can be fed with important nutrients, such 
as oxygen, crucial to tumor growth (197, 198). Nevertheless, these results need to be 
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confirmed with a higher number of tumor samples, not only regarding oligodendrogliomas, 
but also using other types of gliomas, such as astrocytomas. 
To complete our study regarding the passage of molecules across the endothelial 
cells, we decided to evaluate caveolin-1 which is involved in the transcellular pathway. We 
have observed that the expression of caveolin-1 is increased in oligodendrogliomas 
compared with the control. In addition, it seems that the loss of caveolin-1 expression is 
associated with an increased tumor malignancy. Although these results need to be 
confirmed in a higher number of tumor samples, they reinforce the controversy that is 
around caveolin-1 expression. Diverse studies describe that, in some tumors, the 
expression of caveolin-1 is upregulated which is in accordance with our results, when we 
compare non-neoplasic tissue with gliomas. However, several independent groups 
correlate the decrease of this marker with a poor prognosis and outcome (199, 200), which 
also corroborates our findings. Thus, caveolin-1 may have both positive and negative 
impact in tumors (201, 202). It can be considered as tumor suppression of cancer but can 
also promote tumor progression depending on the tumor stages (203). Moreover, recent 
studies have observed that caveolin-1 seems to be upregulated in early response to 
cytotoxic drugs which occurs before drug-resistance (201). This is in agreement to our 
study in the way that the later stages of gliomas can be associated with drug-resistance 
and then, a decrease in caveolin-1 expression compared with earlier stages (201, 203).  
Among the numerous functions of caveolin-1 is the association of this protein to 
vascular permeability. Whatever is the reason for a decrease of caveolin-1 expression, the 
lack of its epithelial expression is associated to an increase of transcellular permeability 
allowing the entrance of uncommon components to the interior of the tumor cell (204, 205) 
which can lead to tumor progression and alter migration and invasiveness capacity of the 
tumor (202, 206). 
Overall, we believe that our results regarding transcellular and paracellular 
permeability can be significant as they reinforce the need to formulate new therapeutic 
strategies to control the barrier function of the endothelium in the neoplastic tissue. 
One other important event regarding tumor´s biology is autophagy. We have 
identified a gradual increase of LC3 expression, with lower levels on controls and highest 
values in anaplastic oligodendroglioma. Previous studies have defended that the increase 
of autophagy is associated to the most malignant forms of gliomas (147). This takes us to 
the paradox of autophagy. On one hand, LC3, which is crucial to autophagy, can act in 
order to prevent the accumulation of damaged proteins and organelles; in this way 
autophagy acts as a tumor suppressor mechanism, but it can also act as a mechanism of 
cell survival in response to cellular stress and promote cellular growth and consequently 
tumor progression (139, 207). This contradictory, but complementary results, can be 
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related to our findings since in early stages, autophagy may be required  to prevent tumor 
growth. However, a dysregulated increase of autophagy may lead to malignant forms of 
cancers (147). Thus, these results establish autophagy as a promising factor to evaluate in 
oligodendrogliomas, as it can be associated with the more aggressive forms of 
oligodendrogliomas. Moreover, recent studies are associating the inhibition of this 
programmed cell death combined to chemotherapy as a way to  increase tumor 
vulnerability and facilitate therapy (208). 
Regarding neuronal cytoskeleton, several studies have identified an increase in NF 
expression in several diseases (209, 210), including glioblastomas (211) and 
oligodendrogliomas (212). The abnormal accumulation of NF leads to an aberrant neuronal 
cytoskeletal organization and consequently to alterations in synapse connection (213). 
Likewise, although needing some further tissue samples, results here presented show that 
anaplastic oligodendrogliomas express high levels of NF, the most representative cell 
marker at neuronal cytoskeleton. There is a lack of consistent information in the literature 
regarding the expression of NF in gliomas and even the significance of such increase in 
other pathologies is not fully understood. Latterly, a new tendency is emerging regarding 
neuronal biomarkers and recent studies have been done with microtubule-associated 
protein 2 (MAP2) and β-tubulin (211, 214, 215). Regarding MAP2, a few studies were 
performed in oligodendrogliomas and have demonstrated a consistent and strong 
expression of this marker revealing a possible useful tool for diagnosis (216). Intriguingly, 
neural migrating cells were previously shown to express MAP2, which was also expressed 
by developing oligodendrocytes and in human oligodendrogliomas (217). However, 
although the correlation of a neuronal marker expression and clinical outcome in 
glioblastoma is of considerable interest, the data from the literature support the limited 
prognostic value of neuronal marker expression in gliomas. 
The chaotic vascular architecture of tumors, is one of the most remarkable 
characteristic when compared with normal tissue (218). There are studies claiming that 
microvasculature changes are extremely important for tumor progression and therefore, 
this can be a prognostic factor for patients´ survival (219-221). Our results are in 
agreement with these findings since we observed an increase of vasculature density in the 
most malignant forms of gliomas. However, the changes in microvasculature are believed 
to occur in early stages of tumors, requiring formation of new vessels and providing more 
oxygen and nutrient support for their growth (165, 218) which can result in extravasation of 
plasma proteins into the interstitial space (222). Conversely, the implications of 
microvasculature go further considering their possible cytoskeleton. For instance, the 
cytoskeleton of a tumor blood vessel is constituted only by tubulin comparing to normal 
blood vessel which also presents actin in its constitution (218). The absence of this 
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component in tumor cytoskeleton, generate hypoxic areas which has been described as 
radioresistant regions (218). Additionally, the irregular vessel density and the altered blood 
flow may lead to a decrease in drug delivery and, then, the effective dose of a 
chemotherapeutic agent can be compromised. Moreover, some chemotherapeutic drugs 
require oxygen supply for their action (218).   
In this way, it is believed that shutdown of tumor blood flow prevents, in some way, 
tumor growth or lead to tumor regression (223). 
Directly related to the vascular network and blood flow are the cover of vessels by 
pericytes which were assessed by the evaluation of α-actin expression, a marker of 
pericytes (36), in our brain samples. In fact, our results show a decrease in α-actin, in the 
early stages of oligodendrogliomas such as the grade I. This decrease can be due not only 
to a loss of pericytes number but also due to a reduction in their contractility capacity which 
affects the organization of the vascular unit. Thus, we can hypothesize that a decrease in 
the number of pericytes could be associated to an increase in vascular permeability with all 
the implication described before for the increase of vascular permeability (222). One other 
important aspect of our results is that oligodendroglioma grade II show an increase of α-
actin as comparing to other grades. In fact, recent studies have published that pericytes 
appears to have different expressions during tumor progression (154). Most important, 
pericytes play a role in angiogenesis and were shown to be decreased in gliomas and to 
compromise endothelial cell function (224) and neurovascular blood flow (225). In addition, 
we should also considerer that therapeutics may have also contributed to the observed 
disruption. Unfortunately, such data were unavailable. 
Finally, we sought to evaluate the presence of proteins involved in the multidrug-
resistance phenomenon. Unfortunately, the potential contribution of P-gp, one of the most 
important proteins involved in drug-resistance, was difficult to assess due to staining 
difficulties. In fact, P-gp was founded to confer MDR phenotype by which a cancer cell 
exposed to an unique anticancer drug becomes simultaneously resistant to that drug and to 
others with different structures and functions (174). However, the few results obtained 
identify an increase of P-gp expression in tumor samples as compared to controls. The 
increase of expression between gliomas and controls is in agreement with previous studies 
which defend that cells are able to adapt to the presence of toxic xenobiotics by increasing 
the expression of drug efflux pumps which protect the cells and increase their survival 
(175-178, 226). However, contradictory results were founded by some authors who 
revealed little or no expression of P-gp (222, 227). Nevertheless, no recent data has been 
published regarding P-gp and oligodendrogliomas, being these results of extremely 
importance since MDR is a huge obstacle to gliomas therapy. Moreover, a recent study 
revealed that even though the expression of P-gp is low and difficult to detect, it can 
   74
significantly affect tumor sensitivity to a variety of important P-gp substrate drugs which 
may have an impact on the availability and distribution of the anticancer drugs (228). 
The inclusion of the evaluation of P-gp expression in this study was aimed to 
assess its importance as a biomarker to assist not only in diagnosis but also in the clinical 
decision of patient treatment regimens.  
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V. Final Considerations and Perspectives 
 
Overall, we believe that this work provides relevant information in the identification of 
potential new biomarkers for human oligodendroglioma diagnosis. Although the results 
here presented were obtained in a yet small number of brain samples, they give rise to very 
promising conclusions. Thus, we can conclude that most of the biomarkers tested can be 
potentially used for oligodendrogliomas diagnosis. In particular, there were some 
biomarkers that may be specifically used for the diagnosis of oligodendrogliomas type III, 
such as β-catenin, LC3, NF and CD31. Most important, increased Sox-2, NG2, P-gp, 
caveolin-1 and decrease α-actin staining have shown to be earlier promising biomarkers of 
the grade I oligodendrogliomas, probably helping in such diagnosis (Fig. V.1). 
These encouraging results may be further completed by using a larger number of 
controls and tumor samples. In addition,since the oncology process is driven by too many 
signalling pathways that can be activated or silenced in parallel or converge to complex 
interactions, we also intend to evaluate, in the future, possible co-expression profiles of 
these biomarkers in the same tissue. These assessments would be interesting to better 
appraise possible interactions between different biomarkers. Furthermore, it would be also 
interesting to analyze the RNA expression of these biomarkers by real-time PCR. This 
approach would help us to clarify the possible post-translational modifications that can 
occur and reflect different levels of RNA expression.   
Finally, we additionally aim to compare different types of gliomas, especially the 
comparison of astrocytomas and oligoastrocytomas with oligodendrogliomas since in 
clinical diagnosis these types of gliomas are extremely difficult to distinguish. These are in 
fact important studies that surely deserve to be performed in order to better understand 
tumor response or progression, which would help to transfer neuro-oncology into the era of 
personalized medicine. 
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Fig. V.1 – Variation in promising biomarkers for oligodendroglioma I (A) and 
oligodendroglioma III (B).  
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